ATE171374T1 - Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln - Google Patents

Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln

Info

Publication number: ATE171374T1
Authority: AT; Austria
Prior art keywords: quinoxalin; aminoalkyl; derivatives; producing; neuroprotective agents
Prior art date: 1991-11-15

Application number

AT92810863T

Other languages

English (en)

Inventor

Klaus Ehrenberger

Dominik Felix

Original Assignee

Phafag Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-15

Filing date

1992-11-09

Publication date

1998-10-15

1992-11-09 Application filed by Phafag Ag filed Critical Phafag Ag

1998-10-15 Application granted granted Critical

1998-10-15 Publication of ATE171374T1 publication Critical patent/ATE171374T1/de

Links

239000004090 neuroprotective agent Substances 0.000 title 1
150000002431 hydrogen Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
102000018899 Glutamate Receptors Human genes 0.000 abstract 1
108010027915 Glutamate Receptors Proteins 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
206010029350 Neurotoxicity Diseases 0.000 abstract 1
206010044221 Toxic encephalopathy Diseases 0.000 abstract 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
-1 methoxy, ethoxy, hydroxy Chemical group 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000007135 neurotoxicity Effects 0.000 abstract 1
231100000228 neurotoxicity Toxicity 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT92810863T 1991-11-15 1992-11-09 Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln ATE171374T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP91119501		1991-11-15

Publications (1)

Publication Number	Publication Date
ATE171374T1 true ATE171374T1 (de)	1998-10-15

Family

ID=8207340

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92810863T ATE171374T1 (de)	1991-11-15	1992-11-09	Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln

Country Status (5)

Country	Link
US (1)	US5563140A (de)
JP (1)	JPH06239747A (de)
AT (1)	ATE171374T1 (de)
DE (1)	DE69227088T2 (de)
ES (1)	ES2123546T3 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2168119T3 (es) *	1995-10-10	2002-06-01	Pfizer	Derivados de quinoxalina para el tratamiento de tinnitus.
AU8695798A (en) *	1997-08-07	1999-03-01	Natan Bauman	Apparatus and method for an auditory stimulator
AT408837B (de) *	1998-06-19	2002-03-25	Phafag Ag	Verwendung von caroverin und/oder caroverin. hydrochlorid zur herstellung von als antioxidantien wirkenden zusammensetzungen und/oder von neuroregenerativen zusammensetzungen
US20030045541A1 (en) *	2001-07-23	2003-03-06	Christopher Bruckner	GABA-Receptor modulators with NMDA-Antagonistic activity
ES2325209T3 (es) *	2002-07-31	2009-08-28	Phafag Aktiengesellschaft	Formulacion farmaceutica y su uso en el tratamiento de enfermedades del oido interno.
US7421086B2 (en)	2002-09-10	2008-09-02	Vivatone Hearing Systems, Llc	Hearing aid system
US20050078843A1 (en) *	2003-02-05	2005-04-14	Natan Bauman	Hearing aid system
US7751580B2 (en) *	2002-09-10	2010-07-06	Auditory Licensing Company, Llc	Open ear hearing aid system
US20060264897A1 (en) *	2005-01-24	2006-11-23	Neurosystec Corporation	Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
JP2008531726A (ja) *	2005-03-04	2008-08-14	ニューロシステックコーポレイション	改良されたガシクリジン製剤
US20070021352A1 (en) *	2005-07-20	2007-01-25	Cypress Bioscience, Inc.	Prevention and treatment of hearing disorders
US8267905B2 (en)	2006-05-01	2012-09-18	Neurosystec Corporation	Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) *	2006-06-09	2010-09-28	Neurosystec Corporation	Flow-induced delivery from a drug mass
WO2008011125A2 (en) *	2006-07-20	2008-01-24	Neurosystec Corporation	Devices, systems and methods for ophthalmic drug delivery
JP2010511595A (ja) *	2006-07-31	2010-04-15	ニューロシステックコーポレイション	遊離塩基ガシクリジンナノ粒子
US20080065002A1 (en) *	2006-09-07	2008-03-13	Neurosystec Corporation	Catheter for Localized Drug Delivery and/or Electrical Stimulation
KR101117129B1 (ko)	2009-09-14	2012-02-24	한국화학연구원	신규한 퀴녹살린 유도체 및 이를 포함하는 줄기세포의 신경세포로의 분화유도용 조성물
EP2522350B1 (de)	2011-05-12	2013-07-31	Immunopharm AG	Verwendung der Wirkstoffkombination aus einem 1-Diethylaminoethyl-3-Chinoxalin-2-on Derivat und einem Oxysterol zur Durchbrechung von Resistenzen bei der Behandlung von Krebs und zur Erhöhung der Immunleistungsfähigkeit bei Krebs, bakteriellen und viralen Erkrankungen, Autoimmunerkrankungen, erhöhter Stress- und Umweltbelastung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE228204C (de) *
EP0032564A1 (de) *	1979-12-28	1981-07-29	Medichemie Ag	Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest
US4975430A (en) *	1989-06-16	1990-12-04	The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University	CNQX and its analogs as therapeutics for degenerative neural diseases
US5037848A (en) *	1989-08-25	1991-08-06	Washington University	Aryl-cycloalkyl-alkanolamines for treatment of epilepsy

1992
- 1992-11-09 ES ES92810863T patent/ES2123546T3/es not_active Expired - Lifetime
- 1992-11-09 AT AT92810863T patent/ATE171374T1/de not_active IP Right Cessation
- 1992-11-09 DE DE69227088T patent/DE69227088T2/de not_active Expired - Fee Related
- 1992-11-16 US US07/975,328 patent/US5563140A/en not_active Expired - Lifetime
- 1992-11-16 JP JP4329024A patent/JPH06239747A/ja active Pending

Also Published As

Publication number	Publication date
US5563140A (en)	1996-10-08
JPH06239747A (ja)	1994-08-30
ES2123546T3 (es)	1999-01-16
DE69227088D1 (de)	1998-10-29
DE69227088T2 (de)	1999-06-02

Similar Documents

Publication	Publication Date	Title
ATE171374T1 (de)	1998-10-15	Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln
MY119150A (en)	2005-04-30	Azetidine derivatives, their preparation and medicaments containing them
FI891548A0 (fi)	1989-03-31	Administrering av monoaminakridiner i kolinergiska bristtillstaond av nervceller.
IL124537A0 (en)	1998-12-06	Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
MY118163A (en)	2004-09-30	Aryl fused azapolycyclic compounds
NO942953D0 (no)	1994-08-09	11-benzaldoksimestradienderivater, fremgangsmåte for deres fremstilling smat legemddel inneholdende slike
DE3462504D1 (de)	1987-04-09	Indole-3-carboxamide derivatives
ATE201671T1 (de)	2001-06-15	Chinolon und acridinon derivate zur behandlung der harninkontinenz
FI945674A0 (fi)	1994-12-01	Substituoidut 2beta-morfoliini-androstaanijohdannaiset
GB2311780B (en)	1999-03-03	Pharmaceutical Piperazine Compounds
NO950177D0 (no)	1995-01-17	Farmakologisk aktive erivater
AU658175B2 (en)	1995-04-06	Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
DE3862660D1 (de)	1991-06-13	2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel.
DE68905361D1 (de)	1993-04-22	Trienische derivate mit chromenischer struktur, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
IL115085A (en)	1999-06-20	Piperazine bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them
GR3024388T3 (en)	1997-11-28	2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties
SE9203824L (sv)	1993-06-28	Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ZA934110B (en)	1994-01-07	Diacylglycerol nicotinates, process fot their preparation and the pharmaceutical compositions which contain them
AU7532787A (en)	1988-01-14	New derivatives of 2,6-piperazinedione, their preparation process and the pharmaceutical compositions containing them
CS548987A2 (en)	1988-09-16	Process for preparing new tetracycline derivatives of indole
AU657423B2 (en)	1995-03-09	Novel piperidine derivatives and process for preparation thereof
FR2708604A1 (fr)	1995-02-10	Utilisation de dérivés de benzènesulfonyl-indole pour la préparation de médicaments.
EP0760375A4 (de)	2002-03-27	Antitumor-indolopyrolocarbazolderivate
DE3860117D1 (de)	1990-06-07	2,3-dihydro-3-phenyl-benzofuran-2-on-acetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES2056025A1 (es)	1994-09-16	Nuevos derivados de indol.

Legal Events

Date	Code	Title	Description
2000-06-15	UEP	Publication of translation of european patent specification
2009-08-15	REN	Ceased due to non-payment of the annual fee